Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Characterization of Alkane Oxidation Products in a Corona-Discharge Reactor Using Ammonia-Doped Ion Mobility-Mass Spectrometry.

Journal of the American Society for Mass Spectrometry·2026
Same author

Unravelling the composition, antioxidant, antimicrobial potential of Himalayan propolis and in vitro evaluation of its cytotoxicity against pancreatic PANC-1 cell lines.

Natural product research·2026
Same author

Brain health care accelerator: A primary care-centered model for scaling dementia diagnosis and care.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Nanocomposite of iron-junk derived goethite and α-MnO<sub>2</sub> nanorod for efficient sequestration of total arsenic from aqueous medium.

Scientific reports·2026
Same author

Internalized stigma, not disability, drives quality-of-life loss in leprosy: A structural analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Next-generation tissue regeneration through theranostic nanogels: rewiring repair pathways for precision and personalised therapy.

International journal of pharmaceutics·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Manifestaciones Clínicas

Priyanka Kumari1, Andrew J Aschenbrenner2,3, Richard B Lipton4,5,6

  • 1Albert Einstein College of Medicine, New York, NY, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La Escala de Deterioro Cognitivo Objetivo (SOMI) predice con precisión la progresión de la enfermedad de Alzheimer en ensayos clínicos. Esta herramienta de evaluación de la memoria muestra perfiles de riesgo consistentes en diferentes tipos de estudios.

Palabras clave:
Enfermedad de AlzheimerDeterioro cognitivoSOMIEnsayos clínicosPredicción de la progresión

Más Videos Relacionados

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from S&#233;zary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from S&#233;zary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Área de la Ciencia:

  • Neurología; Ciencias Cognitivas; Biomarcadores

Sus antecedentes:

  • El deterioro de la memoria es un indicador temprano de la enfermedad de Alzheimer (EA).
  • La Escala de Deterioro Cognitivo Objetivo (SOMI) es un sistema validado que evalúa el declive de la memoria episódica.
  • SOMI ha predicho previamente la progresión en estudios observacionales.

Objetivo del estudio:

  • Evaluar la utilidad predictiva de SOMI para la progresión clínica en el ensayo clínico Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4).
  • Evaluar si el rendimiento predictivo de SOMI es consistente en un entorno de ensayo clínico con criterios de elegibilidad estrictos.

Principales métodos:

  • Se analizaron 1069 participantes cognitivamente normales con exploraciones PET de amiloide positivas.
  • Se determinaron las etapas basales de SOMI utilizando las puntuaciones de la Prueba de Recuerdo Selectivo Libre y Guiado (FCSRT).
  • Los modelos de riesgos proporcionales de Cox evaluaron la asociación entre la etapa de SOMI y la progresión clínica (definida por CDR > 0).

Principales resultados:

  • Las etapas más altas de SOMI al inicio se asociaron significativamente con un mayor riesgo de progresión clínica.
  • Las razones de riesgo para la progresión fueron 1,41 (SOMI-1), 1,74 (SOMI-2) y 2,42 (SOMI 3-4) en comparación con SOMI-0.
  • SOMI siguió siendo un predictor significativo de progresión incluso después de ajustar los niveles de amiloide.

Conclusiones:

  • SOMI predice eficazmente la progresión clínica en individuos asintomáticos con riesgo de enfermedad de Alzheimer dentro de un ensayo clínico.
  • El perfil de riesgo predictivo de SOMI en el estudio A4 fue comparable a los hallazgos de estudios de cohortes longitudinales.
  • SOMI demuestra utilidad como herramienta pronóstica en la investigación clínica de la EA.